The big stem cell news already this week is the acquisition by Fujifilm of Cellular Dynamics International (CDI) for a whopping $307 million dollars or about $16.50 per CDI share. You can read the press release here. Update: The entity is now known as Fujifilm Cellular Dynamics. It was less than two years ago that CDI did […]
Was Fujifilm CDI acquisition a good move by the companies? Read More »
In the last few months the FDA has taken steps toward crystalizing regulatory oversight of stem cell and more broadly cell and tissue-based therapies. These steps come in the form of several draft guidances (see here, here, and here) . The Alliance for Regenerative Medicine (ARM) has responded to the draft guidance on Minimal Manipulation. For example, ARM has
ARM Asks FDA for Clarification on Draft Guidance on Minimal Manipulation Read More »
It’s been exciting to watch the recent developments in using stem cells as the basis for treatments for Type I Diabetes. One of the major players in this arena is the privately-held company, ViaCyte. In this post, I interview ViaCyte President and CEO, Paul Laikind. The topics include their VC-01 product, the Encaptra device, an update on
ViaCyte CEO Laikind Interview: Trial Update, Melton, & Future Read More »
Change is in the air for the California stem cell agency, CIRM. It has a new President, Randy Mills, and CIRM is soon going to be like a new agency too. I recently did an interview with Mills that illuminates some of the big changes that are imminent. I also asked him what his favorite
Radical Vision for CIRM Future: Interview with New Prez Mills Read More »
Cloning of animals is becoming a big, global business, and Hwang Woo-Suk is a major player here. Hwang Woo-Suk and animal cloning It turns out that this reproductive cloning of animals goes well beyond making duplicates of pets for sentimental customers at $100,000 a copy. Cloning of livestock by agribusinesses is becoming fairly common. Some
Cloning Factory in China Has Familiar Partner: Hwang Woo-Suk Read More »
It’s hard to even imagine the world of investigative medicine without the wonderful resource of Clinicaltrials.gov, the global hub for clinical trial listings. I recently interviewed the Director of Clinicaltrials.gov, Dr. Deborah Zarin here, which is a fascinating read. As great as Clinicaltrials.gov is as a resource, unfortunately it faces a new, rapidly growing problem that is a serious
Clinicaltrials.gov Mission At Risk From Proliferating For-Profit Trials Read More »
The California Stem Cell Agency CIRM seems to be in budget cutting mode these days, which from a general perspective makes sense as CIRM seeks to continue operating on its remaining funding through a longer period of time as far out as to 2020. However, not all cuts are necessarily positive. For example, CIRM reportedly (note: many
CIRM 2.0 Should Include Bridges Training Program Read More »
Stem cell-based Regenerative Medicine has huge power for good in the clinic and at the same time great potential for economic development. Those two things go hand in hand. As I argued in my stem cell book, biotech commercialization of stem cells is not a bad thing, but rather if it is done responsibly it
Reflecting on Regenerative Medicine As A Brand Read More »
The future is now. Or so goes the expression. For CIRM, it rings true today. Last year I blogged about what we might expect from the new CIRM that would evolve and take form in the future. I was particularly thinking about this coming incarnation of CIRM, which I called CIRM 2.0, as it related
Welcome CIRM 2.0 and President Mills Read More »
Advanced Cell Technology (ACT; $ACTC) has a new paper out on using human embryonic stem cells (hESC) to make MSCs with potentially powerful therapeutic potential. The paper, entitled Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties, was published in the journal Stem Cells and Development. What’s the scoop on this
Review of New ACT Paper on hESC-derived MSCs Read More »